Thursday, June 19, 2025 6/19/2025

Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy

Award Number: R43CA233108
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/13/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2021

Group Awards By:

View Award Description

Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy - Project Summary Melanoma is an aggressive form of skin cancer with low survival rates in later stages, particular once it has metastasized to distant regions. It is the fifth most commonly diagnosed cancer in the US with an estimated 90,000 new cases diagnosed annually. Melanoma is an ideal candidate for the development of novel immunotherapies that can stimulate the patient’s own immune system against the tumor through localized therapy as it is responsive to these types of therapies and accessible for injection directly into the tumor. Studies have shown that immune activating cytokines such as interleukin-15 (IL-15) can stimulate tumor regression of both the primary injected tumor and distant metastases. However, the range of immune activating cytokines available for clinical use is limited, as the high doses required to induce an anti -tumor response via systemic delivery can cause severe side effects. Efforts to deliver therapy locally to the tumor are hampered by the rapid diffusion rate of the small cytokines, requiring frequent (e.g., 2-3 times a week) intratumoral injections for effective treatment. To enable longer acting IL-15 drug activity, Valitor has developed a patented platform technology for generating soluble clusters of therapeutic proteins attached to single-chain biopolymers. In contrast to other methods of protein-polymer conjugation (e.g., PEGylation), our method of conjugation generates substantially larger conjugates with enhanced drug potency. Conjugate retention within a tumor can be further enhanced by adding copies of a second protein to bind extracellular melanoma-specific antigens such as anti-melanoma-associated chondroitin sulfate proteoglycan (MCSP). Therefore, we anticipate that a bifunctional conjugate made using IL-15 and anti-MCSP antibodies (i.e., mvAnti-MCSPxIL-15) will be retained within the tumor at least 5 times longer than an unmodified cytokine. Our objective during Phase I is to demonstrate proof-of-concept for our multivalent conjugates to provide a sustained effective intratumoral dose of an immunotherapy with minimal systemic exposure following a single local injection. We expect this mvAnti- MCSPxIL-15 therapy will follow a well-defined route to FDA market approval and commercialization, which we will continue during the next phase of this project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2018	VALITOR, INC.	2956 SAN PABLO AVE	BERKELEY	CA	94702	ALAMEDA	USA	Cancer Treatment Research	000	1	11/23/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = -$350 )
2022	2018	VALITOR, INC.	2956 SAN PABLO AVE	BERKELEY	CA	94702	ALAMEDA	USA	Cancer Treatment Research	000	1	10/19/2021	NEW	-$350
														Subtotal = -$350

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Cancer Treatment Research	000	1	8/4/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $298,864 )
2018	2018	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Cancer Treatment Research	000	1	9/13/2018	NEW	$298,864
														Subtotal = $298,864

Grand Total All Awards = $298,514

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy

Award Number: R43CA233108

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/13/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer